Trial · NCT00103844
Results by group64
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 64
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 | Dasatinib | 36 | Participants | ||
| Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 | Imatinib | 14 | Participants | ||
| MCyR at Any Time Prior to Crossover | Dasatinib | MCyR (CCyR + PCyR) | 54 | Participants | |
| MCyR at Any Time Prior to Crossover | Imatinib | MCyR (CCyR + PCyR) | 16 | Participants | |
| MCyR at Any Time Prior to Crossover | Dasatinib | CCyR (0% Ph+ cells) | 44 | Participants | |
| MCyR at Any Time Prior to Crossover | Imatinib | CCyR (0% Ph+ cells) | 9 | Participants | |
| MCyR at Any Time Prior to Crossover | Dasatinib | PCyR (>0% to 35% Ph+ cells) | 10 | Participants | |
| MCyR at Any Time Prior to Crossover | Imatinib | PCyR (>0% to 35% Ph+ cells) | 7 | Participants | |
| Duration of MCyR at 12 Months and 18 Months | Dasatinib | 12 months | 92 | percentage of participants. | |
| Duration of MCyR at 12 Months and 18 Months | Imatinib | 12 months | 74 | percentage of participants. | |
| Duration of MCyR at 12 Months and 18 Months | Dasatinib | 18 months | 90 | percentage of participants. | |
| Duration of MCyR at 12 Months and 18 Months | Imatinib | 18 months | 74 | percentage of participants. | |
| Duration of MCyR at 24 Months | Dasatinib | 90 | Percentage of Participants | ||
| Time to MCyR Prior to Crossover | Dasatinib | 2.8 | Full Range 0.7 to 19.3 | months | |
| Time to MCyR Prior to Crossover | Imatinib | 2.8 | Full Range 2.4 to 5.7 | months | |
| Complete Hematologic Response (CHR) at Any Time Prior to Crossover | Dasatinib | 94 | Participants | ||
| Complete Hematologic Response (CHR) at Any Time Prior to Crossover | Imatinib | 40 | Participants | ||
| Duration of Complete Hematologic Response (CHR) | Dasatinib | 12 months | 92 | percentage of participants | |
| Duration of Complete Hematologic Response (CHR) | Imatinib | 12 months | 82 | percentage of participants | |
| Duration of Complete Hematologic Response (CHR) | Dasatinib | 24 months | 84 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00103844/results